ASX health stocks have fallen this week as Chemist Warehouse hits the bourse through its merger with Sigma Healthcare.

In a report released on February 11, Craig Wong-Pan from RBC Capital maintained a Hold rating on CSL (CMXHF – Research Report), with a price ...

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

This week, the CSL Ltd (ASX: CSL) share price hit a 52-week low. Should investors view the ASX healthcare share as a buy?

In a report released yesterday, David Stanton from Jefferies maintained a Buy rating on CSL (CMXHF – Research Report), with a price target of ...

CSL's latest dividend should be turning investors' heads... The post Everything you need to know about the latest CSL ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL’s balance sheet is in sound condition. Financial risk is low given low revenue cyclicality and product demand is being largely driven by chronic indications. We forecast CSL’s net debt to EBITDA ...

Let's see how this biotech giant performed during the first half of FY 2025. The post CSL share price on watch amid $2.1b ...

Morgan's Scott Power said it had been a volatile week for global equity markets rattled by America's new proposed tariffs.